CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Ionis Pharmaceuticals, Inc. - IONS CFD

45.36
0.87%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.18
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Ionis Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 44.97
Open* 45.34
1-Year Change* 26.86%
Day's Range* 45.05 - 46.03
52 wk Range 32.69-54.44
Average Volume (10 days) 1.18M
Average Volume (3 months) 22.77M
Market Cap 7.27B
P/E Ratio -100.00K
Shares Outstanding 143.47M
Revenue 615.03M
EPS -2.86
Dividend (Yield %) N/A
Beta 0.45
Next Earnings Date Feb 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 45.36 0.77 1.73% 44.59 46.03 44.59
Feb 29, 2024 44.97 -1.63 -3.50% 46.60 46.84 43.92
Feb 28, 2024 46.46 -0.38 -0.81% 46.84 47.55 46.33
Feb 27, 2024 47.34 1.46 3.18% 45.88 47.54 45.72
Feb 26, 2024 46.01 1.10 2.45% 44.91 46.31 44.91
Feb 23, 2024 45.27 1.37 3.12% 43.90 45.32 43.90
Feb 22, 2024 43.90 0.41 0.94% 43.49 44.46 42.03
Feb 21, 2024 43.48 -1.97 -4.33% 45.45 45.84 43.13
Feb 20, 2024 44.31 0.41 0.93% 43.90 45.01 43.80
Feb 16, 2024 44.23 -0.72 -1.60% 44.95 45.48 44.23
Feb 15, 2024 45.06 -3.14 -6.51% 48.20 49.73 44.84
Feb 14, 2024 49.02 0.72 1.49% 48.30 49.26 48.21
Feb 13, 2024 48.55 -0.35 -0.72% 48.90 49.41 48.30
Feb 12, 2024 50.30 -0.32 -0.63% 50.62 51.74 50.06
Feb 9, 2024 51.17 1.56 3.14% 49.61 51.89 49.46
Feb 8, 2024 49.90 0.36 0.73% 49.54 50.26 49.20
Feb 7, 2024 49.44 0.64 1.31% 48.80 49.54 48.51
Feb 6, 2024 49.05 0.91 1.89% 48.14 49.61 48.13
Feb 5, 2024 49.19 2.11 4.48% 47.08 49.57 47.07
Feb 2, 2024 49.66 -0.54 -1.08% 50.20 50.20 49.05

Ionis Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

16:10

Country

US

Event

Ionis Pharmaceuticals Inc at TD Cowen Health Care Conference
Ionis Pharmaceuticals Inc at TD Cowen Health Care Conference

Forecast

-

Previous

-
Wednesday, May 1, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Ionis Pharmaceuticals Inc Earnings Release
Q1 2024 Ionis Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Friday, May 31, 2024

Time (UTC)

21:00

Country

US

Event

Ionis Pharmaceuticals Inc Annual Shareholders Meeting
Ionis Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 587.367 810.456 729.264 1122.6 599.674
Revenue 587.367 810.456 729.264 1122.6 599.674
Cost of Revenue, Total 14.116 10.842 11.947 4.384 1.82
Gross Profit 573.251 799.614 717.317 1118.21 597.854
Total Operating Expense 997.558 849.269 901.346 822.912 661.046
Selling/General/Admin. Expenses, Total 150.295 170.947 332.222 286.644 244.622
Research & Development 833.147 634.953 526.877 465.688 414.604
Unusual Expense (Income) 32.527 30.3 66.196 0
Operating Income -410.191 -38.813 -172.082 299.687 -61.372
Interest Income (Expense), Net Non-Operating 9.876 10.798 37.592 39.765 -14.602
Other, Net -7.274 -1.133 -0.062 -0.686 -0.182
Net Income Before Taxes -257.985 -29.148 -134.552 338.766 -76.156
Net Income After Taxes -269.722 -28.597 -479.743 287.259 -117.115
Minority Interest 0 0 35.48 -9.116 58.756
Net Income Before Extra. Items -269.722 -28.597 -444.263 278.143 -58.359
Net Income -269.722 -28.597 -444.263 278.143 273.741
Income Available to Common Excl. Extra. Items -269.722 -28.597 -444.263 278.143 -58.359
Income Available to Common Incl. Extra. Items -269.722 -28.597 -444.263 278.143 273.741
Dilution Adjustment 0
Diluted Net Income -269.722 -28.597 -444.263 278.143 273.741
Diluted Weighted Average Shares 141.848 141.021 139.612 153.164 134.056
Diluted EPS Excluding Extraordinary Items -1.90149 -0.20279 -3.18213 1.81598 -0.43533
Diluted Normalized EPS -2.58703 -0.05286 -3.04106 2.18246 -0.43533
Total Extraordinary Items 332.1
Gain (Loss) on Sale of Assets 149.604
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 188.411 130.524 151.889 159.767 133.791
Revenue 188.411 130.524 151.889 159.767 133.791
Cost of Revenue, Total 2.537 1.343 3.686 1.515 4.745
Gross Profit 185.874 129.181 148.203 158.252 129.046
Total Operating Expense 267.306 244.672 359.908 218.921 219.305
Selling/General/Admin. Expenses, Total 46.142 45.516 47.95 34.416 33.802
Research & Development 229.927 197.813 308.272 182.99 180.758
Operating Income -78.895 -114.148 -208.019 -59.154 -85.514
Interest Income (Expense), Net Non-Operating 19.219 16.49 13.436 7.732 -5.064
Other, Net -17.772 -15.285 0.649 4.713 -12.297
Net Income Before Taxes -77.448 -112.943 -44.33 -46.709 -102.875
Net Income After Taxes -85.29 -124.323 -52.43 -46.992 -105.135
Minority Interest 0
Net Income Before Extra. Items -85.29 -124.323 -52.43 -46.992 -105.135
Net Income -85.29 -124.323 -52.43 -46.992 -105.135
Income Available to Common Excl. Extra. Items -85.29 -124.323 -52.43 -46.992 -105.135
Income Available to Common Incl. Extra. Items -85.29 -124.323 -52.43 -46.992 -105.135
Diluted Net Income -85.29 -124.323 -52.43 -46.992 -105.135
Diluted Weighted Average Shares 143.098 142.735 142.046 141.95 141.794
Diluted EPS Excluding Extraordinary Items -0.59603 -0.87101 -0.36911 -0.33105 -0.74146
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.64735 -0.87101 -1.05369 -0.33105 -0.74146
Unusual Expense (Income) -11.3
Gain (Loss) on Sale of Assets 149.604
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2202.69 2345.05 2130.71 2720.6 2207.89
Cash and Short Term Investments 1986.87 2114.97 1892.38 2499.54 2084.07
Cash & Equivalents 276.472 869.191 397.664 683.287 278.82
Short Term Investments 1710.4 1245.78 1494.71 1816.26 1805.25
Total Receivables, Net 25.538 61.896 76.204 63.034 12.759
Accounts Receivable - Trade, Net 25.538 61.896 76.204 63.034 12.759
Total Inventory 22.033 24.806 21.965 18.18 8.582
Other Current Assets, Total 168.254 143.374 140.163 139.839 102.473
Total Assets 2533.88 2611.69 2389.75 3233.11 2667.78
Property/Plant/Equipment, Total - Net 255.838 196.069 181.077 166.251 132.16
Property/Plant/Equipment, Total - Gross 343.554 298.722 240.264 193.634
Accumulated Depreciation, Total -87.716 -102.653 -74.013 -61.474
Intangibles, Net 29.005 27.937 25.674 24.032
Other Long Term Assets, Total 75.344 41.567 50.034 320.59 303.706
Total Current Liabilities 311.561 240.55 598.898 273.005 280.294
Accounts Payable 17.921 11.904 17.199 16.067 28.66
Accrued Expenses 196.494 129.97 155.889 106.152 77.629
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.32 0.926 316.11 13.749
Other Current Liabilities, Total 96.826 97.75 109.7 150.786 160.256
Total Liabilities 1960.99 1839.95 1646.47 1762.02 1619.7
Total Long Term Debt 1182.72 1228.02 623.529 770.3 632.971
Long Term Debt 1182.72 1228.02 623.529 770.3 632.971
Capital Lease Obligations
Other Liabilities, Total 466.709 371.379 424.046 505.26 567.359
Total Equity 572.887 771.737 743.282 1471.09 1048.08
Common Stock 0.142 0.141 0.14 0.14 0.138
Additional Paid-In Capital 2059.85 1964.17 1895.52 2203.78 2047.25
Retained Earnings (Accumulated Deficit) -1429.62 -1159.9 -1131.31 -707.534 -967.293
Other Equity, Total -57.48 -32.668 -21.071 -25.29 -32.016
Total Liabilities & Shareholders’ Equity 2533.88 2611.69 2389.75 3233.11 2667.78
Total Common Shares Outstanding 142.058 141.21 140.366 140.34 137.929
Minority Interest 213.453 139.081
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 2584.65 2616.75 2542.62 2202.69 2152.13
Cash and Short Term Investments 2235.58 2385.39 2346.78 1986.87 1981.66
Cash & Equivalents 352.06 424.79 309.031 276.472 314.993
Short Term Investments 1883.52 1960.6 2037.75 1710.4 1666.67
Total Receivables, Net 142.359 27.956 13.914 25.538 6.645
Accounts Receivable - Trade, Net 142.359 27.956 13.914 25.538 6.645
Total Inventory 25.634 25.538 22.2 22.033 20.645
Other Current Assets, Total 181.075 177.872 159.724 168.254 143.173
Total Assets 2933.97 2971.13 2885.22 2533.88 2421.97
Property/Plant/Equipment, Total - Net 245.238 268.352 264.306 255.838 180.806
Intangibles, Net 29.605
Other Long Term Assets, Total 104.083 86.025 78.296 75.344 59.434
Total Current Liabilities 404.21 287.975 259.221 311.561 283.454
Accounts Payable 5.615 24.021 10.499 17.921 20.545
Accrued Expenses 152.749 134.067 130.862 189.279 158.412
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 9.952 8.903 8.239 7.535 4.97
Other Current Liabilities, Total 235.894 120.984 109.621 96.826 99.527
Total Liabilities 2618.51 2542.83 2398.65 1960.99 1827.61
Total Long Term Debt 1279.29 1315.26 1184.38 1182.72 1249.5
Long Term Debt 1279.29 1315.26 1184.38 1182.72 1249.5
Other Liabilities, Total 935.01 939.592 955.054 466.709 294.656
Total Equity 315.46 428.301 486.57 572.887 594.361
Common Stock 0.143 0.143 0.143 0.142 0.142
Additional Paid-In Capital 2148 2118.31 2089.36 2059.85 2034.55
Retained Earnings (Accumulated Deficit) -1786.65 -1639.24 -1553.95 -1429.62 -1377.19
Other Equity, Total -46.037 -50.913 -48.983 -57.48 -63.14
Total Liabilities & Shareholders’ Equity 2933.97 2971.13 2885.22 2533.88 2421.97
Total Common Shares Outstanding 143.393 143.167 143.023 142.058 142.017
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -269.722 -28.597 -479.743 287.259 214.985
Cash From Operating Activities -274.37 30.799 35.892 345.627 602.906
Cash From Operating Activities 14.328 15.487 13.365 12.54 10.706
Amortization 2.415 2.352 2.064 1.912 1.822
Deferred Taxes 0 0 341.729 0.911 -290.516
Non-Cash Items -28.962 155.375 232.032 211.806 166.484
Cash Interest Paid 2.898 4.778 6.247 9.87 9.592
Changes in Working Capital 7.571 -113.818 -73.555 -168.801 499.425
Cash From Investing Activities -262.636 194.906 274.477 -41.274 -929.563
Capital Expenditures -15.721 -11.955 -35.12 -30.905 -13.608
Other Investing Cash Flow Items, Total -246.915 206.861 309.597 -10.369 -915.955
Cash From Financing Activities -55.295 245.933 -596.609 100.021 475.865
Financing Cash Flow Items -10.982 -168.954 -558.097 -138.354 0
Issuance (Retirement) of Stock, Net 6.373 101.317 -38.512 141.375 475.865
Issuance (Retirement) of Debt, Net -50.686 313.57 0 97 0
Net Change in Cash -592.719 471.527 -285.623 404.467 149.19
Cash Taxes Paid 5.01 0.038 25.855 9.041 0
Foreign Exchange Effects -0.418 -0.111 0.617 0.093 -0.018
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -124.323 -269.722 -217.292 -170.3 -65.165
Cash From Operating Activities -133.992 -274.37 -74.175 -49.746 -31.65
Cash From Operating Activities 2.604 14.328 11.301 7.484 3.701
Amortization 0.607 2.415 1.805 1.197 0.592
Deferred Taxes 0
Non-Cash Items 42.124 -28.962 91.563 64.125 32.983
Cash Taxes Paid 0.293 5.01 0.002 0.002 0.002
Cash Interest Paid 0.089 2.898 2.204 1.544 0.594
Changes in Working Capital -55.004 7.571 38.448 47.748 -3.761
Cash From Investing Activities -325.64 -262.636 -474.783 -290.853 -287.549
Capital Expenditures -10.472 -15.721 -11.582 -6.04 -2.705
Other Investing Cash Flow Items, Total -315.168 -246.915 -463.201 -284.813 -284.844
Cash From Financing Activities 492.087 -55.295 -4.276 -6.11 -7.325
Financing Cash Flow Items 489.566 -10.982 -10.217 -9.572 -9.173
Issuance (Retirement) of Stock, Net 2.56 6.373 6.03 3.462 1.848
Foreign Exchange Effects 0.104 -0.418 -0.964 -0.565 -0.154
Net Change in Cash 32.559 -592.719 -554.198 -347.274 -326.678
Issuance (Retirement) of Debt, Net -0.039 -50.686 -0.089 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 14.9755 21463816 27482 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 10.1142 14496361 81444 2023-06-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 9.1286 13083727 19680 2023-06-30 LOW
Bellevue Asset Management AG Investment Advisor 6.5447 9380300 -131600 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.9748 7130179 72474 2023-06-30 LOW
ClearBridge Investments, LLC Investment Advisor/Hedge Fund 3.6192 5187204 -204377 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.773 3974453 -93881 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 2.5762 3692429 -100615 2023-06-30 LOW
Tweedy, Browne Company LLC Investment Advisor 2.4705 3540858 -188 2023-06-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 2.1599 3095670 1982628 2023-06-30 LOW
BVF Partners L.P. Hedge Fund 1.9857 2846015 285254 2023-06-30 LOW
Deep Track Capital LP Hedge Fund 1.9774 2834069 0 2023-06-30 MED
Camber Capital Management LP Hedge Fund 1.7443 2500000 575000 2023-06-30 MED
ARK Investment Management LLC Investment Advisor 1.651 2366367 -56264 2023-09-30 LOW
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 1.5137 2169500 45000 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5049 2156868 86918 2023-06-30 LOW
Macquarie Investment Management Investment Advisor 1.0458 1498882 4979 2023-06-30 LOW
First Trust Advisors L.P. Investment Advisor 0.9231 1323032 -315911 2023-06-30 MED
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.9047 1296647 178306 2022-12-31 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.8367 1199220 12827 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ionis Pharmaceuticals Company profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Industry: Biotechnology & Medical Research (NEC)

2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

Gold

2,083.15 Price
+1.890% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0108%
Overnight fee time 22:00 (UTC)
Spread 0.50

US100

18,286.90 Price
+1.410% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

0.63 Price
+4.530% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

79.49 Price
+1.850% 1D Chg, %
Long position overnight fee 0.0266%
Short position overnight fee -0.0485%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading